MOG79–90 Peptide in Complex with Recombinant MHC Class II Molecules Ameliorates Experimental Autoimmune Encephalomyelitis

T. Batsalova, M. Vestberg, R. Holmdahl, B. Dzhambazov
2010 Biotechnology & Biotechnological Equipment  
The recent advancement in the field of biomedical technologies has opened up new possibilities in the treatment of autoimmune disorders such as multiple sclerosis (MS). Here, we report the production of soluble complexes between the myelin oligodendrocytic glycoprotein (MOG) 79-90 peptide and a genetically engineered murine MHC class II molecule A q . Using mouse model of MS, we demonstrate that the generated complexes are functional and able to ameliorate the clinical signs and reduce the
more » ... and reduce the incidence of experimental autoimmune encephalomyelitis (EAE). Our findings offer a new possibility for the treatment of chronically active autoimmune inflammation such as multiple sclerosis.
doi:10.1080/13102818.2010.10817822 fatcat:h4ft2lyl7vehleepv5bcwvd4de